Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUTENSIN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension,Mild essential hypertension
Hypertension
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Extensively metabolized in the liver via deacetylation and hydrolysis; reserpine is metabolized by CYP3A4 and carboxyl esterase.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Protein binding is approximately 50-60%, primarily to albumin and alpha-1-acid glycoprotein.
~90%, primarily to albumin
Volume of distribution (Vd) is approximately 1.6 L/kg, indicating extensive tissue distribution and accumulation in adipose tissue. This high Vd contributes to the long half-life.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability is variable, estimated at approximately 50-60% due to extensive first-pass hepatic metabolism. Bioavailability is route-specific: oral only, as no parenteral formulations are clinically available.
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: contraindicated due to thiazide component.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for use in children; safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lowest dose (0.5 tablet once daily); monitor for hypotension and electrolyte imbalance.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause mental depression, especially in patients with history of depression,Use caution in patients with gastric ulcers (may increase gastric acid secretion),Avoid in patients undergoing electroconvulsive therapy (ECT),May cause hypotension and bradycardia,Discontinue 2 weeks before elective surgery
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to any component,Active peptic ulcer (may exacerbate),History of electroconvulsive therapy,Parkinsonism,Depression (especially with suicidal tendencies)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes) unless advised by a doctor. Thiazide diuretics can cause potassium depletion, but reserpine may blunt this effect. Limit alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neural tube defects, cardiovascular anomalies) at high doses. Second and third trimesters: risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use during pregnancy, especially after 20 weeks gestation.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk. M/P ratio: approximately 1:1. Potential for serious adverse effects in the nursing infant, including respiratory depression, bradycardia, and gastrointestinal disturbances. Breastfeeding is not recommended during maternal therapy with Rautensin.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy-induced physiologic changes (increased plasma volume, renal clearance) may lower reserpine serum levels. However, due to teratogenic and neonatal risks, Rautensin is contraindicated in pregnancy. No dosing adjustments are recommended because use is not advised. Consider alternative antihypertensives with established safety profiles.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Rautensin is a combination of Rauwolfia alkaloids (e.g., reserpine) and a thiazide diuretic (e.g., bendroflumethiazide). It is rarely used today due to better-tolerated alternatives. Monitor for orthostatic hypotension, especially in elderly. Check serum potassium and uric acid regularly due to thiazide component. Reserpine can cause depression and nasal congestion; discontinue if depressive symptoms emerge. Avoid in patients with history of depression or peptic ulcer disease.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop abruptly as it may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness.,This medication can cause drowsiness; avoid driving until you know how it affects you.,Report any signs of depression, mood changes, or unusual tiredness.,Avoid alcohol and other sedatives; they can increase dizziness and drowsiness.,If you experience nasal congestion, it may be due to the medication; consult your doctor.,Regular blood tests are needed to monitor potassium and uric acid levels.,Use effective contraception if of childbearing age; discuss with your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUTENSIN vs ALDORIL 15, answered by our medical review team.
RAUTENSIN is a Antihypertensive that works by Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUTENSIN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUTENSIN is: 1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUTENSIN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUTENSIN is classified as Category C. Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neur. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.